Lifespan: Why We Age―and Why We Don't Have To

David A. Sinclair, a professor of genetics at Harvard Medical School and codirector of the Paul F. Glenn Center for the Biological Mechanisms of Aging, argues that aging is not an inevitable part of life but a treatable disease. Drawing on decades of research, personal narrative, and emerging technologies, he contends that prolonged healthy lifespans are imminent and that humanity must prepare for the consequences.

Sinclair opens with the story of his grandmother Vera, a Hungarian-born adventurer who embodied youthful spirit well into her 70s but declined sharply in her final decade, becoming frail before dying at 92. He recounts the death of his mother, Diana, from lung failure, describing the violent reality of her final moments. These experiences anchor his central contention: Modern medicine has extended average lifespan without extending healthspan, the portion of life spent free of disease and disability. He compares the current moment in aging research to the period just before the Wright brothers achieved powered flight.

In Part I, Sinclair proposes an evolutionary origin story for aging, tracing it to a primordial "survival circuit" that allowed early organisms to pause reproduction and repair DNA damage during environmental stress. This circuit became the ancestor of longevity gene pathways conserved across species, including sirtuins (enzymes that regulate gene expression and DNA repair), mTOR (a growth-regulating enzyme complex), and AMPK (a metabolic enzyme that responds to low energy levels). He critiques prior theories of aging, noting that antioxidant supplements have failed to extend maximum lifespan in animals despite the popularity of the Free Radical Theory, which proposes that chemically reactive molecules damage cells and accelerate aging. He presents what he considers decisive counterevidence against mutations as the primary cause of aging: Successful animal cloning demonstrates that old cells retain all the genetic information needed to produce a young organism, meaning DNA is not irreversibly lost with age.

This leads to Sinclair's central thesis, the Information Theory of Aging. He distinguishes between digital information (DNA, which is robust and reliably copied) and analog information (the epigenome, the system of chemical tags and protein structures that determines which genes are active in each cell). He uses the analogy of a piano: Every cell has the same roughly 20,000 genes (the keys), but the epigenome acts as the pianist, determining which keys are played. Over time, the pianist hits wrong notes with increasing frequency, disrupting cellular function. Sinclair traces this theory to his work in Leonard Guarente's lab at MIT, where he discovered that broken DNA causes the Sir2 protein, the first known sirtuin, to leave its normal post at the mating-type genes, which determine yeast cell type and are normally kept silent. The protein rushes to repair sites, and when it returns, it sometimes lands in the wrong place, altering gene expression. This redistribution, accumulating over a lifetime, causes cells to lose their identity, a process Sinclair calls "ex-differentiation." His team demonstrated that an extra copy of the SIR2 gene could stabilize the genome and extend yeast lifespan by 30 percent.

To test whether this mechanism operates in mammals, Sinclair's lab created ICE (Inducible Changes to the Epigenome) mice by inserting an enzyme that cuts DNA at non-gene-bearing sites. The resulting breaks distracted sirtuins without creating mutations. The ICE mice aged prematurely, developing thinning gray hair, cataracts, arthritis, bone loss, and frailty, and their epigenetic clock—a DNA-based measure of biological age—showed them to be about 50 percent older than untreated siblings. The experiment demonstrated that epigenetic disruption alone causes aging. Sinclair argues that aging should therefore be classified as a disease, critiquing the "whack-a-mole" approach to medicine: Eliminating all cardiovascular disease would add only 1.5 years to average lifespan, and eliminating all cancer only 2.1 years, because other age-related causes of death increase exponentially to fill the gap.

Part II surveys interventions. Sinclair reviews lifestyle measures including calorie restriction, intermittent fasting, exercise, and cold exposure, all of which activate longevity gene pathways. Turning to pharmaceuticals, he discusses rapamycin, which extended mouse lifespan by 9 to 14 percent through inhibition of mTOR; metformin, a diabetes drug costing less than five dollars a month associated with reduced rates of dementia, cardiovascular disease, cancer, and frailty; and resveratrol, a polyphenol found in red wine that activated SIRT1, a mammalian sirtuin enzyme linked to stress-response regulation, extending yeast lifespan by about 36 percent. He discusses NAD boosters, particularly nicotinamide mononucleotide (NMN), a precursor to NAD, a cellular molecule essential to energy metabolism and sirtuin activity. His lab showed that NMN reversed mitochondrial aging in old mice within a week and restored vascular function. He tells the story of his father, Andrew, who began taking metformin and NMN in his mid-70s and experienced a dramatic renewal, outpacing younger friends on hikes and starting a second career.

Sinclair then presents emerging biotechnologies. Mayo Clinic researchers Darren Baker and Jan van Deursen showed that destroying senescent "zombie" cells, which have stopped dividing but release inflammatory molecules that damage surrounding tissue, extended mouse lifespan by 20 to 30 percent. Separately, Mayo Clinic researcher James Kirkland found that a short course of the drugs quercetin and dasatinib extended mouse lifespan by 36 percent. The most transformative frontier is cellular reprogramming. Japanese stem cell researcher Shinya Yamanaka discovered in 2006 that four transcription factors—gene-regulatory proteins—(Oct4, Klf4, Sox2, and c-Myc) can reprogram adult cells into pluripotent stem cells, cells capable of becoming many different cell types, a finding that won the 2012 Nobel Prize. Researcher Juan Carlos Izpisua Belmonte of the Salk Institute for Biological Studies showed in 2016 that intermittent activation of these factors extended the lifespan of prematurely aging mice by 40 percent but caused lethal tumors when overactivated. Sinclair's graduate student Yuancheng Lu removed the cancer-causing c-Myc and delivered only three factors (OSK) to mice with crushed optic nerves. The treatment regenerated nerve axons and restored vision in old mice, with no tumors arising even after a year. Sinclair theorizes that cells retain a biological backup of youthful epigenetic information and that the TET enzymes, which remove methyl tags from DNA, help correct age-related errors.

Sinclair also surveys diagnostic technologies that will contribute to longer lives, including precision medicine tailored to individual genomes, biosensors that monitor biomarkers in real time, and solutions to the organ shortage crisis such as xenotransplantation—cross-species organ transplantation—from gene-edited pigs.

Part III addresses the societal implications of extended lifespans. Sinclair estimates that combined advances could add approximately 33 years to average life expectancy, bringing it to about 113, with no fixed biological limit. He confronts objections: Earth may already be at its carrying capacity of 8 billion; longer lives could entrench political power; Social Security was designed when the worker-to-beneficiary ratio was 41:1, whereas today it is 3:1; and the gap in life expectancy between the richest and poorest Americans grew from 1.2 years in the 1970s to 13 years by 2018. He counters with historical analogy, arguing that nineteenth-century London's population boom forced innovations in sanitation and public health that transformed the city. He contends that healthy older people are an underutilized economic asset, citing economist Dana Goldman's estimate that delayed aging could yield over $7 trillion in economic benefits over 50 years in the United States.

Sinclair calls for classifying aging as a disease, increasing public funding for aging research, ensuring universal access to longevity treatments, and rethinking work structures through proposals such as "skillbaticals," government-supported paid years off for retraining. He discloses his personal regimen, including daily NMN, resveratrol, and metformin, stressing these are personal choices and not medical advice. The book closes with Sinclair hiking in the Australian bush near Sydney with his father, wife Sandra, and son Benjamin, along the same trail his grandmother Vera once walked with him, affirming his conviction that nothing about aging is inevitable.